(Q42595188)

3 November 2017

title

Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study (English)

1 reference

borderline personality disorder

3 November 2017

main subject

0 references

author name string

S Bellino

1

1 reference

3 November 2017

E Paradiso

2

1 reference

3 November 2017

P Bozzatello

3

1 reference

3 November 2017

F Bogetto

4

1 reference

3 November 2017

language of work or name

English

0 references

publication date

21 August 2008

1 reference

Journal of Psychopharmacology

3 November 2017

published in

1 reference

3 November 2017

volume

24

1 reference

3 November 2017

issue

3

1 reference

3 November 2017

page(s)

333-339

1 reference

Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials.

3 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Duloxetine and other antidepressants in the treatment of patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Fluoxetine and impulsive aggressive behavior in personality-disordered subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Norepinephrine function in personality disorder: plasma free MHPG correlates inversely with life history of aggression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Revising axis V for DSM-IV: a review of measures of social functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Effects of duloxetine on painful physical symptoms associated with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Developmental psychopathology and neurobiology of aggression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

The assessment of anxiety states by rating

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Time course of depression-symptom improvement during treatment with duloxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Duloxetine in the treatment of major depressive disorder: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Serotonin transporter polymorphism and borderline or antisocial traits among low-income young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Association between serotonin transporter gene and borderline personality disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Monoamine oxidase a gene is associated with borderline personality disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Fluoxetine in borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

The biology of impulsivity and suicidality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Neurobiological correlates of diagnosis and underlying traits in patients with borderline personality disorder compared with normal controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Hyperresponsiveness of hypothalamic-pituitary-adrenal axis to combined dexamethasone/corticotropin-releasing hormone challenge in female borderline personality disorder subjects with a history of sustained childhood abuse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

5HT2A receptor binding is increased in borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Emergence of intense suicidal preoccupation during fluoxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

Duloxetine in practice-based clinical settings: assessing effects on the emotional and physical symptoms of depression in an open-label, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881108095715

21 January 2018

Identifiers

DOI

10.1177/0269881108095715

1 reference

3 November 2017

1 reference